High STK40 Expression as an Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Low-Grade Gliomas

References

• Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16(7):896–913. doi:10.1093/neuonc/nou087
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1
   PubMed Web of Science ®Google Scholar
• Han C, He Y, Chen L, et al. Low expression of APOB mRNA or its hypermethylation predicts favorable overall survival in patients with low-grade glioma. Onco Targets Ther. 2020;13:7243–7255. doi:10.2147/OTT.S257794
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra0708126
   PubMed Web of Science ®Google Scholar
• Huang SP, Chan YC, Huang SY, Lin YF. Overexpression of PSAT1 gene is a favorable prognostic marker in lower-grade gliomas and predicts a favorable outcome in patients with IDH1 mutations and chromosome 1p19q codeletion. Cancers. 2019;12(1):13. doi:10.3390/cancers12010013
   PubMed Web of Science ®Google Scholar
• Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8):1338–1345. doi:10.1200/JCO.2007.13.9337
   PubMed Web of Science ®Google Scholar
• Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer. 2006;106(6):1358–1363. doi:10.1002/cncr.21733
   PubMed Web of Science ®Google Scholar
• Li L, Sun L, Gao F, et al. Stk40 links the pluripotency factor Oct4 to the Erk/MAPK pathway and controls extraembryonic endoderm differentiation. Proc Natl Acad Sci USA. 2010;107(4):1402–1407. doi:10.1073/pnas.0905657107
   PubMed Web of Science ®Google Scholar
• Yu H, He K, Wang L, et al. Stk40 represses adipogenesis through translational control of CCAAT/enhancer-binding proteins. J Cell Sci. 2015;128(15):2881–2890.
   PubMed Web of Science ®Google Scholar
• He K, Hu J, Yu H, et al. Serine/Threonine Kinase 40 (Stk40) functions as a novel regulator of skeletal muscle differentiation. J Biol Chem. 2017;292(1):351–360. doi:10.1074/jbc.M116.719849
   PubMed Web of Science ®Google Scholar
• Wang L, Yu H, Cheng H, et al. Deletion of Stk40 impairs definitive erythropoiesis in the mouse fetal liver. Cell Death Dis. 2017;8(3):e2722. doi:10.1038/cddis.2017.148
   PubMed Web of Science ®Google Scholar
• Maubant S, Tahtouh T, Brisson A, et al. LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers. Oncotarget. 2018;9(32):22586–22604. doi:10.18632/oncotarget.25187
   PubMedGoogle Scholar
• Li S, Yang R, Sun X, et al. Identification of SPP1 as a promising biomarker to predict clinical outcome of lung adenocarcinoma individuals. Gene. 2018;679:398–404. doi:10.1016/j.gene.2018.09.030
   PubMed Web of Science ®Google Scholar
• Shen Y, Liu J, Zhang L, et al. Identification of potential biomarkers and survival analysis for head and neck squamous cell carcinoma using bioinformatics strategy: a study based on TCGA and GEO datasets. Biomed Res Int. 2019;2019:7376034. doi:10.1155/2019/7376034
   PubMed Web of Science ®Google Scholar
• Lu X, Li G, Liu S, Wang H, Zhang Z, Chen B. Bioinformatics analysis of KIF1A expression and gene regulation network in ovarian carcinoma. Int J Gen Med. 2021;14:3707–3717. doi:10.2147/IJGM.S323591
   PubMed Web of Science ®Google Scholar
• Vivian J, Rao AA, Nothaft FA, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314–316. doi:10.1038/nbt.3772
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–416.e411.
   PubMed Web of Science ®Google Scholar
• Xu H, Wang H, Li G, Jin X, Chen B. The immune-related gene ELF3 is a novel biomarker for the prognosis of ovarian cancer. Int J Gen Med. 2021;14:5537–5548. doi:10.2147/IJGM.S332320
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Young JS, Prados MD, Butowski N. Using genomics to guide treatment for glioblastoma. Pharmacogenomics. 2018;19(15):1217–1229. doi:10.2217/pgs-2018-0078
   PubMed Web of Science ®Google Scholar
• Xi Z, Zhang R, Zhang F, Ma S, Feng T. KLF11 expression predicts poor prognosis in glioma patients. Int J Gen Med. 2021;14:2923–2929. doi:10.2147/IJGM.S307784
   PubMed Web of Science ®Google Scholar
• Peng S, Wang G, Cheng Z, Guo Z. IRF7 as an immune-related prognostic biomarker and associated with tumor microenvironment in low-grade glioma. Int J Gen Med. 2021;14:4381–4393. doi:10.2147/IJGM.S324307
   PubMed Web of Science ®Google Scholar
• Cho SY, Kim S, Kim G, Singh P, Kim DW. Integrative analysis of KIF4A, 9, 18A, and 23 and their clinical significance in low-grade glioma and glioblastoma. Sci Rep. 2019;9(1):4599. doi:10.1038/s41598-018-37622-3
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu N, Xu X, et al. Clinical significance of Iroquois Homeobox Gene - IRX1 in human glioma. Mol Med Rep. 2018;17(3):4651–4656.
   PubMed Web of Science ®Google Scholar
• Pang CH, Du W, Long J, Song LJ. Mechanism of SEMA3B gene silencing and clinical significance in glioma. Genet Mol Res. 2016;15(1). doi:10.4238/gmr.15017664
   Web of Science ®Google Scholar
• Yang L, Zhang H, Yao Q, Yan Y, Wu R, Liu M. Clinical significance of SASH1 expression in glioma. Dis Markers. 2015;2015:383046. doi:10.1155/2015/383046
   PubMed Web of Science ®Google Scholar
• Taccioli C, Garofalo M, Chen H, et al. Repression of esophageal neoplasia and inflammatory signaling by anti-miR-31 delivery in vivo. J Natl Cancer Inst. 2015;107(11):djv220. doi:10.1093/jnci/djv220
   PubMedGoogle Scholar
• Durzynska I, Xu X, Adelmant G, et al. STK40 is a pseudokinase that binds the E3 ubiquitin ligase COP1. Structure. 2017;25(2):287–294. doi:10.1016/j.str.2016.12.008
   PubMed Web of Science ®Google Scholar